Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence

Table 19 Polypectomy

Ref.	Year	Country	Study design	n	Polyp morphology	Procedure	Medication	Relative risk
Pan et al[31]	2012	New Zealand	Retrospective	145	Size: 2-40 mm (average size 9.6 mm)	Polypectomy	Aspirin (continued)	Incidence of PPB 5.5%
Manocha et al[32]	2012	United States	Retrospective	502	Size: 2-50 mm	Polypectomy	Aspirin (continued)	Incidence of PPB 3.2%
Park et al[43]	2018	South Korea	Prospective	3887	Size: < 10 mm and ≥ 10 mm	Polypectomy	Aspirin (ceased 5-7 d before and restarted 1 d after)	Incidence of PPB 3.4%
Lin et al[107]	2018	United States	Retrospective	20374	Size: < 20 mm and ≥ 20 mm	Polypectomy	Aspirin (continuation or cessation N/S)	Incidence of PPB 0.92%
Kishida et al[41]	2019	Japan	Retrospective	12876	Size: < 10 mm and ≥ 10 mm	Polypectomy	Aspirin either: (1) Ceased 3-5 d before (cases before 2012); (2) Continued (cases after 2012)	Incidence of PPB 0.6%
Amato et al[108]	2019	Italy	Prospective	1504	Size: ≥ 10 mm	Polypectomy	Aspirin (ceased up to 9 d before)	Incidence PPB 4.2%
Watanabe et al[109]	2020	Japan	Retrospective	1050	Size: < 10 mm and ≥ 10 mm	Polypectomy	Aspirin (continued)	Incidence of PPB 4.3%

PPB: Post-procedural bleeding; N/S: Not stated.